Get the Daily Brief
Latest Biotech News
Menin inhibitors advance as targeted therapy for KMT2A‑rearranged leukemia
New data spotlight menin inhibitors as a targeted therapeutic strategy for KMT2A‑rearranged acute leukemias, a genetically defined and aggressive subtype. Researchers and early‑stage developers...
Endpoints Signal launches; BPSI Q4 2025 reads 78 – biopharma mood stays dour
Endpoints News launched Endpoints Signal, an intelligence platform led by Tom Randall, and published the inaugural Biopharma Sentiment Index (BPSI) for Q4 2025. The BPSI scored 78—well below a...
FDA biosimilar plan collides with patent office policy – regulatory friction grows
The FDA proposed guidance to streamline biosimilar approvals—aiming to slash time and cost for copycat biologics—while critics say the U.S. Patent and Trademark Office’s tougher stance on inter...
Quantifying α‑synuclein seeds in CSF—new assay could change Parkinson’s trials
Researchers described an endpoint‑dilution seed amplification assay (SAA) that quantifies α‑synuclein seeds in cerebrospinal fluid with improved precision, enabling measurement of pathological...
TCR therapy and vascular research map barriers in ovarian cancer treatment
Researchers outlined both clinical obstacles for T‑cell receptor (TCR) therapies in ovarian cancer and new insights into VEGF‑driven vascular pathways that fuel tumor growth. The TCR review...
RNAi candidate cuts HBV markers — path to functional cure
Researchers published a Nature Communications study demonstrating an RNA interference (RNAi) therapeutic that substantially reduces hepatitis B virus (HBV) markers and supports the prospect of a...
Menin inhibitors: breakthrough targeted option for KMT2A leukemia
New research and clinical interest are converging on menin inhibitors as a targeted strategy for KMT2A-rearranged acute leukemias. Studies show menin blockade disrupts the leukemogenic program...
Endpoint dilution SAA quantifies α-syn seeds — diagnostic advance
Researchers unveiled an endpoint dilution seed amplification assay (SAA) that quantifies cerebrospinal fluid α-synuclein seeds with improved precision, delivering a more granular biomarker for...
Engineered ACE2 decoy neutralizes multi-variant SARS-CoV-2
A study in the Journal of Biomedical Science reported an engineered ACE2 decoy receptor that neutralizes mutant and escape variants of SARS-CoV-2. The decoy binds spike protein across divergent...
FDA biosimilar push runs into patent-office resistance
The FDA announced plans to streamline biosimilar approval pathways to mimic generic regulation, promising lower development costs and faster market entry. Industry leaders touted potential savings...
mTORC1 in ILC2s: neuro-immune axis drives allergic lung inflammation
A Nature Communications 2025 study identified mTORC1 signaling in group 2 innate lymphoid cells (ILC2s) as a central node linking neuronal cues to allergic lung inflammation. The authors used...
AML survival pathways: THRAP3 and RPPH1 drive therapy resistance
Two mechanistic studies chart distinct molecular drivers that enable acute myeloid leukemia (AML) cells to evade cell death and sustain aggressive disease. One report identifies THRAP3 as a...
TCR therapy in ovarian cancer: delivery and specificity challenges persist
A global research synthesis highlights ongoing hurdles for T-cell receptor (TCR) therapies in ovarian cancer, including tumor heterogeneity, on-target off-tumor toxicity, and insufficient...
Fucosidase dependency: new target for rotavirus and norovirus replication
Researchers discovered that both rotavirus and norovirus replication depend on host fucosidase activity, revealing a conserved glycan-processing vulnerability in two major gastrointestinal...
Sepsis outcomes tied to IgG levels and ferroptosis mechanisms
Two studies advance the clinical and mechanistic understanding of sepsis. A multicenter analysis led by Hu et al. found serum IgG levels predict sepsis outcomes and may identify patients who...
RNAi for HBV: Nature Communications flags a possible functional cure
Researchers published a Nature Communications paper reporting an RNA interference (RNAi) therapeutic that significantly reduces hepatitis B virus markers and advances toward a functional cure. The...
Menin inhibitors: targeted therapy advances for KMT2A‑rearranged leukemia
Researchers and clinical teams reported that menin inhibitors continue to emerge as the leading targeted approach for KMT2A‑rearranged acute leukemias, a historically treatment‑resistant subset....
ACE2 decoy receptor neutralizes SARS‑CoV‑2 variants — blocking mutants too
A team led by Lin et al. published work in the Journal of Biomedical Science describing an engineered ACE2 decoy receptor that neutralizes multiple mutant SARS‑CoV‑2 strains. The decoy binds...
Jumbo phage targets MBL Pseudomonas — therapeutic candidate for resistant infections
Paranos and colleagues reported discovery and characterization of a jumbo bacteriophage active against metallo‑β‑lactamase (MBL)–producing Pseudomonas aeruginosa strains. The study describes host...
α‑Synuclein seed quantification: new CSF assay sharpens Parkinson’s diagnostics
Researchers unveiled an endpoint dilution seed amplification assay (SAA) that quantifies α‑synuclein seeding activity in cerebrospinal fluid with higher precision. The team reported improved...